Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
Marc Krause, Yikang Zhu, Maximilian Huhn, et al.
European Archives of Psychiatry and Clinical Neuroscience (2018) Vol. 268, Iss. 7, pp. 625-639
Open Access | Times Cited: 182

Showing 1-25 of 182 citing articles:

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
Maximilian Huhn, Adriani Nikolakopoulou, Johannes Schneider‐Thoma, et al.
The Lancet (2019) Vol. 394, Iss. 10202, pp. 939-951
Open Access | Times Cited: 1372
<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>
Christoph U. Correll, Nina R. Schooler
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 519-534
Open Access | Times Cited: 553
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Ewgenij Proschak, Holger Stark, Daniel Merk
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 2, pp. 420-444
Closed Access | Times Cited: 412
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Kenneth S. Koblan, Justine Kent, Seth C. Hopkins, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 16, pp. 1497-1506
Open Access | Times Cited: 246
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Junting Zhou, Xueyang Jiang, Siyu He, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 20, pp. 8881-8914
Closed Access | Times Cited: 232
The clinical characterization of the patient with primary psychosis aimed at personalization of management
Mario Maj, Jim van Os, Marc D. Binder, et al.
World Psychiatry (2021) Vol. 20, Iss. 1, pp. 4-33
Open Access | Times Cited: 224
EPA guidance on treatment of negative symptoms in schizophrenia
Silvana Galderisi, Stefan Kaiser, István Bitter, et al.
European Psychiatry (2021) Vol. 64, Iss. 1
Open Access | Times Cited: 133
Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
Elias Wagner, Spyridon Siafis, Piyumi Fernando, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 104
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
Christoph U. Correll, Amber Martin, Charmi Patel, et al.
Schizophrenia (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 93
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Hui Wu, Spyridon Siafis, Tasnim Hamza, et al.
Schizophrenia Bulletin (2022) Vol. 48, Iss. 3, pp. 643-654
Open Access | Times Cited: 73
Primary and Secondary Negative Symptoms in Schizophrenia
Sergey Mosolov, Polina A. Yaltonskaya
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 72
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 60
Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis
Marc Krause, Yikang Zhu, Maximilian Huhn, et al.
European Neuropsychopharmacology (2018) Vol. 28, Iss. 6, pp. 659-674
Closed Access | Times Cited: 120
Pathophysiology of negative symptom dimensions of schizophrenia – Current developments and implications for treatment
Indrit Bègue, Stefan Kaiser, Matthias Kirschner
Neuroscience & Biobehavioral Reviews (2020) Vol. 116, pp. 74-88
Open Access | Times Cited: 92
Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
Naielly Rodrigues da Silva, Felipe V. Gomes, Andreza B. Sonego, et al.
Pharmacological Research (2020) Vol. 156, pp. 104749-104749
Open Access | Times Cited: 72
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108236-108236
Open Access | Times Cited: 49
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Gilly Wolf, Sandeep Singh, Karin Blakolmer, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 44-58
Closed Access | Times Cited: 38
Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
Spyridon Siafis, Hui Wu, Dongfang Wang, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 8, pp. 3267-3277
Open Access | Times Cited: 38
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis
Nicholas Fabiano, Stanley Wong, Carl Zhou, et al.
European Neuropsychopharmacology (2024) Vol. 92, pp. 62-73
Open Access | Times Cited: 10
Psychosis superspectrum II: neurobiology, treatment, and implications
Roman Kotov, William T. Carpenter, David C. Cicero, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 5, pp. 1293-1309
Closed Access | Times Cited: 9
Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia
Jing Huang, AnMei Chen, Hua Jin, et al.
The Journal of Clinical Psychiatry (2025) Vol. 86, Iss. 1
Closed Access | Times Cited: 1
Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis
Marc Krause, Maximilian Huhn, Johannes Schneider‐Thoma, et al.
European Neuropsychopharmacology (2018) Vol. 29, Iss. 1, pp. 32-45
Closed Access | Times Cited: 71
Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis
Maximilian Huhn, Adriani Nikolakopoulou, Johannes Schneider‐Thoma, et al.
FOCUS The Journal of Lifelong Learning in Psychiatry (2020) Vol. 18, Iss. 4, pp. 443-455
Open Access | Times Cited: 66
<p>Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm</p>
Giancarlo Cerveri, Camilla Gesi, Claudio Mencacci
Neuropsychiatric Disease and Treatment (2019) Vol. Volume 15, pp. 1525-1535
Open Access | Times Cited: 61
Page 1 - Next Page

Scroll to top